These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9097868)

  • 61. Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders.
    Raingeard I; Courtet P; Renard E; Bringer J
    Diabetes Care; 2004 Mar; 27(3):847-8. PubMed ID: 14988322
    [No Abstract]   [Full Text] [Related]  

  • 62. A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia.
    Marrazzi MA; Kinzie J; Luby ED
    Int Clin Psychopharmacol; 1995 Sep; 10(3):173-6. PubMed ID: 8675970
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Topical Application of Naltrexone to the Ocular Surface of Healthy Volunteers: A Tolerability Study.
    Liang D; Sassani JW; McLaughlin PJ; Zagon IS
    J Ocul Pharmacol Ther; 2016 Mar; 32(2):127-32. PubMed ID: 26741052
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of antidepressant-resistant bulimia with naltrexone.
    Jonas JM; Gold MS
    Int J Psychiatry Med; 1986-1987; 16(4):305-9. PubMed ID: 3557806
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High-dose naltrexone therapy and dietary counseling for obesity.
    Mitchell JE; Morley JE; Levine AS; Hatsukami D; Gannon M; Pfohl D
    Biol Psychiatry; 1987 Jan; 22(1):35-42. PubMed ID: 3790639
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Psychopharmacology of eating disorders.
    Mitchell JE
    Ann N Y Acad Sci; 1989; 575():41-8; discussion 49. PubMed ID: 2517383
    [No Abstract]   [Full Text] [Related]  

  • 67. Anhedonia to music and mu-opioids: Evidence from the administration of naltrexone.
    Mallik A; Chanda ML; Levitin DJ
    Sci Rep; 2017 Feb; 7():41952. PubMed ID: 28176798
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Minimum effective naltrexone dose to antagonise etorphine immobilisation and prevent the complications of renarcotisation in domestic goats.
    O'Dell JH; Kock MD; Thompson PN; Meyer LCR
    Vet Rec; 2017 Nov; 181(18):481. PubMed ID: 28978715
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis.
    Manudhane AP; Schrom KP; Ezaldein HH; Armile JA
    Dermatol Online J; 2019 Jun; 25(6):. PubMed ID: 31329393
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of long-term therapy with naltrexone on body weight in obesity.
    Atkinson RL; Berke LK; Drake CR; Bibbs ML; Williams FL; Kaiser DL
    Clin Pharmacol Ther; 1985 Oct; 38(4):419-22. PubMed ID: 4042525
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Naltrexone and bulimic symptoms.
    Igoin-Apfelbaum L; Apfelbaum M
    Lancet; 1987 Nov; 2(8567):1087-8. PubMed ID: 2889994
    [No Abstract]   [Full Text] [Related]  

  • 72. Naltrexone as a treatment of self-injurious behavior: a case report.
    Griengl H; Dantendorfer K
    Eur Psychiatry; 2001 Apr; 16(3):193-4. PubMed ID: 11353600
    [No Abstract]   [Full Text] [Related]  

  • 73.
    Sablaban IM; Sivananthan M
    J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):620. PubMed ID: 33146546
    [No Abstract]   [Full Text] [Related]  

  • 74. Treatment of chronic anorexia nervosa with opiate blockade.
    Luby ED; Marrazzi MA; Kinzie J
    J Clin Psychopharmacol; 1987 Feb; 7(1):52-3. PubMed ID: 3818993
    [No Abstract]   [Full Text] [Related]  

  • 75. Negative allesthesia and decreased endogenous opiate system activity in anorexia nervosa.
    Melchior JC; Rigaud D; Colas-Linhart N; Rozen R; Fantino M; Apfelbaum M
    Pharmacol Biochem Behav; 1990 Apr; 35(4):885-8. PubMed ID: 2140609
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Naltrexone for Self-Injury in Borderline Personality With Venlafaxine-Associated Hyponatremia.
    DeLucia B
    J Clin Psychopharmacol; 2017 Dec; 37(6):743-745. PubMed ID: 28891834
    [No Abstract]   [Full Text] [Related]  

  • 77. Use of Anticraving Agents in the Treatment of Exhibitionism and Frotteuristic Disorder.
    Blum AW; Grant JE
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):611-612. PubMed ID: 34519457
    [No Abstract]   [Full Text] [Related]  

  • 78. Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy.
    Hota D; Srinivasan A; Dutta P; Bhansali A; Chakrabarti A
    Pain Med; 2016 Apr; 17(4):790-1. PubMed ID: 26814245
    [No Abstract]   [Full Text] [Related]  

  • 79. Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children.
    Cazzullo AG; Musetti MC; Musetti L; Bajo S; Sacerdote P; Panerai A
    Eur Neuropsychopharmacol; 1999 Jun; 9(4):361-6. PubMed ID: 10422898
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Low-Dose Naltrexone as First Option for Fibromyalgia Patients: A Case Series.
    de Carvalho JF
    Isr Med Assoc J; 2024 Aug; 26(7):441-442. PubMed ID: 39082454
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.